Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fexlamose
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aer Therapeutics Doses First Patient in Phase 2 COPD Trial of Fexlamose
Details : AER-01 (fexlamose) is a small molecule mucin inhibitor, which is being developed as a chronic treatment for COPD and asthma.
Product Name : AER-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2025
Lead Product(s) : Fexlamose
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AER-01
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Canaan
Deal Size : $36.0 million
Deal Type : Series A Financing
Details : Proceeds from the financing will be used to advance the development of AER-01, the company’s novel inhaled small molecule mucolytic drug designed to liquefy mucus plugs in the lungs of patients with chronic obstructive pulmonary disease (COPD).
Product Name : AER-01
Product Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : AER-01
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Canaan
Deal Size : $36.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?
Reset All
